GSK and CureVac forged their relationship during the Covid-19 pandemic, setting out to develop messenger RNA vaccines that could protect against the novel coronavirus and other infectious diseases.
Chinese drugmaker Jiangsu Hengrui Pharmaceuticals has agreed to develop up to 12 of its drugs with British pharmaceutical giant GSK. Hengrui Pharma granted GSK an exclusive worldwide licence to its ...
GSK (LSE:GSK) has entered a collaboration with Wave Life Sciences to advance a GalNAc-siRNA hepatology candidate into its ...
Biopharmaceutical company GSK is growing its Massachusetts work force, announcing plans to move its vaccines research and development and infectious disease teams from suburban Maryland to Cambridge ...
GSK’s CEO-led transformation boosts M&A and R&D to navigate the HIV patent cliff. Click here to read this latest analysis of ...
GSK said it is ending the development program for the small-molecule drug Belrestotug. The British pharmaceutical giant said Tuesday that the decision is based on a new interim analyses from phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results